SCOPUS 정보 검색 플랫폼

Volumn 86, Issue 4, 2016, Pages 200-202

Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab

(3) Riddell, Amy a Goodship, Tim b Bingham, Coralie a

a ROYAL DEVON AND EXETER HOSPITAL (United Kingdom)

b NEWCASTLE UNIVERSITY (United Kingdom)

Author keywords

Atypical hemolytic uremic syndrome; Complement; Eculizumab

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; ECULIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CASE REPORT; DRUG MONITORING; HUMAN; KIDNEY TRANSPLANTATION; MALE; PROCEDURES; RECURRENT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT C3; COMPLEMENT C5; COMPLEMENT SYSTEM PROTEINS; DRUG MONITORING; HUMANS; KIDNEY TRANSPLANTATION; MALE; RECURRENCE;

EID: 84995799460 PISSN: 03010430 EISSN: None Source Type: Journal
DOI: 10.5414/CN108808 Document Type: Article

Times cited : (4)

References (5)

1
- 84878589219
- Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome
- Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368: 2169-2181.
- (2013) N Engl J Med. , vol.368 , pp. 2169-2181
- Legendre, C.M.¹ Licht, C.² Muus, P.³ Greenbaum, L.A.⁴ Babu, S.⁵ Bedrosian, C.⁶ Bingham, C.⁷ Cohen, D.J.⁸ Delmas, Y.⁹ Douglas, K.¹⁰ Eitner, F.¹¹ Feldkamp, T.¹² Fouque, D.¹³ Furman, R.R.¹⁴ Gaber, O.¹⁵ Herthelius, M.¹⁶ Hourmant, M.¹⁷ Karpman, D.¹⁸ Lebranchu, Y.¹⁹ Mariat, C.²⁰ more..

2
- 84870534251
- Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation
- Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C; French Study Group for Atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012; 12: 3337-3354.
- (2012) Am J Transplant. , vol.12 , pp. 3337-3354
- Zuber, J.¹ Le Quintrec, M.² Krid, S.³ Bertoye, C.⁴ Gueutin, V.⁵ Lahoche, A.⁶ Heyne, N.⁷ Ardissino, G.⁸ Chatelet, V.⁹ Noël, L.H.¹⁰ Hourmant, M.¹¹ Niaudet, P.¹² Frémeaux-Bacchi, V.¹³ Rondeau, E.¹⁴ Legendre, C.¹⁵ Loirat, C.¹⁶

3
- 84908611206
- Dynamics of complement activation in aHUS and how to monitor eculizumab therapy
- Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014; 124: 1715-1726.
- (2014) Blood. , vol.124 , pp. 1715-1726
- Noris, M.¹ Galbusera, M.² Gastoldi, S.³ McOr, P.⁴ Banterla, F.⁵ Bresin, E.⁶ Tripodo, C.⁷ Bettoni, S.⁸ Donadelli, R.⁹ Valoti, E.¹⁰ Tedesco, F.¹¹ Amore, A.¹² Coppo, R.¹³ Ruggenenti, P.¹⁴ Gotti, E.¹⁵ Remuzzi, G.¹⁶

4
- 81255195666
- Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): An update on a previous case report
- Ohanian M, Cable C, Halka K. Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol. 2011; 3: 45-50.
- (2011) Clin Pharmacol. , vol.3 , pp. 45-50
- Ohanian, M.¹ Cable, C.² Halka, K.³

5
- 84921802401
- Dissecting complement blockade for clinic use
- Risitano AM. Dissecting complement blockade for clinic use. Blood. 2015; 125: 742-744. Cross-Ref PubMed
- (2015) Blood. , vol.125 , pp. 742-744
- Risitano, A.M.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.